期刊文献+

浅蓝菌素脂质体的制备及其对肿瘤细胞体外增殖影响的研究 被引量:1

Study on preparation of cerulenin liposomes and its effects on proliferation of tumor cells in vitro
下载PDF
导出
摘要 目的制备浅蓝菌素脂质体并研究其对HER2/neu(erbB-2)原癌基因过表达肿瘤细胞株体外增殖的影响。方法采用超声薄膜分散法制备浅蓝菌素脂质体;正交设计优化处方;HPLC法测定药物包封率及脂质体中药物浓度;离心加速实验及冷藏实验考察脂质体稳定性;活细胞计数法测定细胞生长曲线;MTT法测定游离浅蓝菌素及浅蓝菌素脂质体对细胞的增殖抑制作用。结果浅蓝菌素脂质体的平均粒径为134.3 nm,稳定性良好,最佳处方条件下药物包封率为(53.45±3.67)%,脂质体中药物质量浓度为(1.126±0.065)mg/mL,剂量依赖性抑制SK-B r3和SK-Ov3细胞的增殖,IC50分别为9.62和9.32μmol.L-1。结论该制备工艺和处方可行,所制备的浅蓝菌素脂质体对SK-B r3细胞和SK-Ov3细胞有明显的增殖抑制作用,且作用强于游离浅蓝菌素。 Objective To optimize the preparation of cerulenin iposomes and investigate the effect of cerulenin liposomes on proliferation of tumor cells overexpressing HER-2/neu in vitro. Methods Cerulenin embedded in liposomes was assayed by HPLC and the embedding rate of cerulenin was calculated. Particle size and distribution of cerulenin liposomes were investigated by laser scatter and stability of liposomes was investigated by centrifugal acceleration experiment and deep freezing. The growth curves of cells treated with cerulenin liposomes at different concentrations were determined by counting the cell number and ICso of cerulenin liposomes was determined by MTT method. Results The average diameter of cerulenin liposomes was 134.3 nm with good stability. The embedding rate of cerulenin into liposomes was 53.45% , and the concentration of cerulenin in liposomes was 1. 126 mg/mL. The liposomes inhibited the growth of SK-Br3 and SK-Ov3 cells in vitro in a dose-dependent manner and the IC50 of cerulenin liposomes on SK- Br3 and SK-Ov3 cells was 9.62 × 10^-6 and 9.32 × 10^-6 mol/L respectively. Conclusion The cerulenin liposomes that were prepared with the modified formulation inhibited the proliferation of SK-Br3 and SK- Ov3 cells in vitro with IC50 less than those of free cerulenin.
出处 《广东药学院学报》 CAS 2009年第2期126-130,共5页 Academic Journal of Guangdong College of Pharmacy
关键词 浅蓝菌素 脂质体 包封率 肿瘤细胞 IC50 Cerulenin liposomes embedding rate tumor cells IC50
  • 相关文献

参考文献10

  • 1MENENDEZ JA, VELLON L, MEHMI I,et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu(erb B- 2) oncogene overexpression in cancer cells [ J ]. PNAS, 2004,101 (29) : 10715 - 10720.
  • 2VISCA P, SEBASTIANI V, BOTTI C, et al. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma [ J ]. Anticancer Res, 2004,24 ( 6 ) :4169 -4173.
  • 3OMURA S. Cerulenin [ J ]. Methods Enzymol, 1981,72 : 520 - 532.
  • 4CHAYAKULKEEREE M, RUDE T H, TOFFALETTI D L, et al. Fatty acid synthesis is essential for survival of Cryptococcus neoformans and a potential fungicidal target [ J ]. Antimicrob Agents Chemother ,2007,51 ( 10 ) : 3537 - 3545.
  • 5RASSMANN A, HENKE A, JARASCH N, et al. The human fatty acid synthase: a new therapeutic target for coxsackievirus B3-induced diseases [ J ]. Antiviral Res, 2007, 76(2) : 150 - 158.
  • 6HOT S, HO Y P, WONG W Y, et al. Pharmacokinetics and safety of a unilametlar liposomal formulation of amphotericin B ( AmBisome ) in rabbits [ J ]. Biomed Pharmacother,2007,61 (9) :578 -587.
  • 7TOMODA H, IGARASHI K, TANAKA Y, et al. Pharmacokinetics and safety of an unilamellar liposomal formulation of ampho2-tericin B ( AmBisome ) in rabbits [ J ]. Antimicrob Agents Chemother, 1994,38 (4) : 713 - 718.
  • 8HIROSHI T, KAZUAKI I, YOSHITAKE T, et al. Biosynthetic preparation of labeled Cerulenin with high specific radioactivity [ J ]. J Antibio, 1987,11 ( 10 ) : 1457 - 1460.
  • 9张奇,邓英杰.冻融法制备5-氟尿嘧啶脂质体及其稳定性考察[J].沈阳药科大学学报,2000,17(2):87-89. 被引量:35
  • 10GABIZON A, GOREN D, BARENHOLZ Y. Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models [ J ]. Isr J Med Sci, 1988,24 ( 9 - 10) :512 -517.

二级参考文献7

共引文献34

同被引文献20

  • 1王炜琴,赵小英,徐根波,梁赟.脂肪酸合成酶抑制剂抑制人多发性骨髓瘤细胞增殖及诱导其凋亡的研究[J].中华血液学杂志,2006,27(10):675-677. 被引量:4
  • 2Van Poppel H, Tombal B. Chemoprevention of prostate cancer with nutrients and supplements. Cancer management and re- search, 2011 ;3:91 - 100.
  • 3Teiten MH, Gaascht F, Eifes S, et al. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr,2010 Mar;5 ( 1 ) :61 - 74.
  • 4Hatcher H, Planalp R, Cho J, et al. Curcumin from ancient medi- cine to current clinical trials. Cell Mol Life Sci,2008,65:1631 - 1652.
  • 5Slusarz A, Shenouda NS, Sakla MS, et al. Common botanical com- pounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 2010 ;70:3382 - 3390.
  • 6Piantino CB, Salvadori FA, Ayres PP, et al. An evaluation of the anti - neoplastic activity of curcumin in prostate cancer cell lines. Int Braz J Urol. 2009 ;35:354 -360.
  • 7Itokawa H, Shi Q, Akiyama T, et al. Recent advances in the investigation of curcuminoids. Chin Med. 2008 Sep 17 ;3:11.
  • 8Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007 ;4 : 807 - 818.
  • 9Yallapu MM, Dobberpuhl MR, Maher DM, et al. Design of Cur- cumin loaded Cellulose Nanoparticles for Prostate Cancer.
  • 10Kirsh VA, Mayne ST, Peters U, et al. A prospective study ofly- copene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prey. 2006 ; 15:92 - 98.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部